DK1100922T3 - Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine - Google Patents

Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine

Info

Publication number
DK1100922T3
DK1100922T3 DK99938897T DK99938897T DK1100922T3 DK 1100922 T3 DK1100922 T3 DK 1100922T3 DK 99938897 T DK99938897 T DK 99938897T DK 99938897 T DK99938897 T DK 99938897T DK 1100922 T3 DK1100922 T3 DK 1100922T3
Authority
DK
Denmark
Prior art keywords
ospc
borrelia burgdorferi
borreliacid
epitopes
vaccine
Prior art date
Application number
DK99938897T
Other languages
English (en)
Inventor
Steven N Callister
Steven D Lovrich
Ronald F Schell
Dean A Jobe
Original Assignee
Gundersen Lutheran Medical Fou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gundersen Lutheran Medical Fou filed Critical Gundersen Lutheran Medical Fou
Application granted granted Critical
Publication of DK1100922T3 publication Critical patent/DK1100922T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK99938897T 1998-07-31 1999-07-30 Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine DK1100922T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9495598P 1998-07-31 1998-07-31
PCT/US1999/017270 WO2000006745A1 (en) 1998-07-31 1999-07-30 Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Publications (1)

Publication Number Publication Date
DK1100922T3 true DK1100922T3 (da) 2008-06-16

Family

ID=22248146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99938897T DK1100922T3 (da) 1998-07-31 1999-07-30 Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine

Country Status (13)

Country Link
US (2) US6210676B1 (da)
EP (1) EP1100922B1 (da)
JP (1) JP3631960B2 (da)
AT (1) ATE386805T1 (da)
AU (1) AU5328299A (da)
CA (1) CA2332570C (da)
CY (1) CY1107944T1 (da)
DE (1) DE69938183T2 (da)
DK (1) DK1100922T3 (da)
ES (1) ES2302385T3 (da)
NO (1) NO329227B1 (da)
PT (1) PT1100922E (da)
WO (1) WO2000006745A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US7060281B1 (en) 1999-06-18 2006-06-13 Research Foundation Of The State University Of New York Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
AU2001281145A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
EP1865062A3 (en) * 2000-08-18 2008-01-09 Research Foundation Of State University Of New York Altered OspA of Borrelia burgdorferi
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
RU2260047C2 (ru) * 2003-10-23 2005-09-10 Государственное учреждение Научно-исследовательский институт биохимии Сибирского отделения Российской академии медицинских наук Рекомбинантная плазмидная днк, обеспечивающая синтез иммунодоминантного белка borrelia garinii, используемого для диагностики лайм-боррелиоза (варианты)
UA99719C2 (ru) * 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110262475A1 (en) * 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CN103229055A (zh) 2010-09-27 2013-07-31 康奈尔大学 莱姆病的诊断方法
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
UY34745A (es) 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
WO2016049148A1 (en) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions and methods for te diagnosis of lyme disease
EP3720489A1 (en) 2017-12-04 2020-10-14 Intervet International B.V. Canine lyme disease vaccine
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
EP0519016A1 (en) 1990-03-07 1992-12-23 F.Hoffmann-La Roche & Co. Aktiengesellschaft Method for diagnosis of lyme disease
CA2084413A1 (en) 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
FI955150A7 (fi) * 1993-04-29 1995-12-28 Baxter Ag OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistam iseksi
US5656451A (en) 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
WO1995011998A1 (en) * 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5558993A (en) 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
DE69731982T2 (de) 1996-03-26 2005-12-22 Cylex, Inc. Verfahren zur messung der lymphozytenfunktion
DE69718903T2 (de) * 1996-05-02 2003-12-04 Dakocytomation Denmark A/S, Glostrup Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA

Also Published As

Publication number Publication date
CY1107944T1 (el) 2013-09-04
DE69938183D1 (de) 2008-04-03
NO20010412L (no) 2001-03-29
CA2332570A1 (en) 2000-02-10
JP2002523019A (ja) 2002-07-30
CA2332570C (en) 2009-12-08
ATE386805T1 (de) 2008-03-15
DE69938183T2 (de) 2009-02-19
JP3631960B2 (ja) 2005-03-23
NO329227B1 (no) 2010-09-20
US6464985B1 (en) 2002-10-15
PT1100922E (pt) 2008-05-30
EP1100922B1 (en) 2008-02-20
EP1100922A1 (en) 2001-05-23
WO2000006745A1 (en) 2000-02-10
AU5328299A (en) 2000-02-21
ES2302385T3 (es) 2008-07-01
NO20010412D0 (no) 2001-01-24
US6210676B1 (en) 2001-04-03

Similar Documents

Publication Publication Date Title
DK1100922T3 (da) Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine
Bonavia et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
NO995458D0 (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
NO2010021I2 (no) Denosumab
EA200600905A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
FR2794865B1 (fr) Methode de detection precoce des flavivirus et ses applications
EP1881064A2 (en) HCV-Anti-core monoclonal antibodies
WO2005016132A3 (en) Diagnostics for sars virus
DE60144201D1 (de) Lawsonia intracellularis Impfstoff
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
ATE188746T1 (de) Adeno-assozierter virus - dessen diagnostischen anwendung für frühe abtreibung
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2003026700A3 (fr) Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2004113566A3 (en) Disease related protein network
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
King Monoclonal antibody studies on rabies-related viruses
WO2002085924A3 (en) ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE